Effect of Severe Renal Impairment on the Safety, Tolerability, and Pharmacokinetics of AMG 986

INTRODUCTION: AMG 986 is a first-in-class, novel apelin receptor small molecule agonist initially developed for the treatment of heart failure (HF). The safety and pharmacokinetics (PK) of AMG 986 in participants with renal impairment (RI) remains unknown. METHODS: This phase 1 study compared the sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Trivedi, Ashit, Mather, Omar, Vega, Silvia, Simiens, Mary Ann, Hellawell, Jennifer, Lee, Edward
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885944/
https://www.ncbi.nlm.nih.gov/pubmed/35092583
http://dx.doi.org/10.1007/s40268-021-00380-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885944/
https://www.ncbi.nlm.nih.gov/pubmed/35092583
http://dx.doi.org/10.1007/s40268-021-00380-1

Ejemplares similares